2-Methoxystypandrone inhibits signal transducer and activator of transcription 3 and nuclear factor-κB signaling by inhibiting Janus kinase 2 and IκB kinase

Cancer Science

Volumn 105, Issue 4, 2014, Pages 473-480

  Kuang, Shan ^a   Qi, Chunting ^a   Liu, Jiawei ^b   Sun, Xiaoxiao ^a   Zhang, Qing ^a   Sima, Zhenhua ^b   Liu, Jingli ^a   Li, Wuguo ^b   Yu, Qiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

2 Methoxystypandrone; Anticancer drug; Janus kinase 2 signal transducer and activator of transcription 3 pathway; Natural compound; Tumor necrosis factor nuclear factor B pathway

Indexed keywords

2 METHOXYSTYPANDRONE; ALPHA INTERFERON; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; I KAPPA B; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL DEATH; CELL GROWTH; CELL STRAIN HEK293; CELL STRAIN HEPG2; CELL SURVIVAL; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PLANT ROOT; POLYGONUM CUSPIDATUM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THIN LAYER CHROMATOGRAPHY;

2-METHOXYSTYPANDRONE; ANTICANCER DRUG; JANUS KINASE 2/SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 PATHWAY; NATURAL COMPOUND; TUMOR NECROSIS FACTOR-Α/NUCLEAR FACTOR-ΚB PATHWAY;

APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-6; JANUS KINASE 2; MEDICINE, CHINESE TRADITIONAL; NAPHTHOQUINONES; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898446801     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12359     Document Type: Article

References (32)

1. Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an Oncogene. Cell 1999; 98: 295-303.
2. Bowman T, Garcia R, Turkson J et al. STATs in oncogenesis. Oncogene 2000; 19: 2474-88.
3. Garcia R, Bowman TL, Guillian N, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20: 2499-513.
4. Mora LB, Buettner R, Seigne J et al. Constitutive activation of STAT3 in human prostate tumors and cell lines direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-66.
5. Kijima T, Niwa H, Steinman RA et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002; 13: 355.
6. Chan KS, Carbajal S, Kiguchi K et al. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 2004; 64: 2382-9.
7. Corvinus FM, Orth C, Moriggl R et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005; 7: 545.
8. Niu G, Bowman T, Huang M et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001.
9. Blaskovich MA, Sun J, Cantor A et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-9.
10. Iwamaru A, Szymanski S, Iwado E et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007; 26: 2435-44.
11. Burger R, Le Gouill S, Tai Y-T et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 2009; 8: 26-35.
12. Lin L, Hutzen B, Zuo M et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70: 2445-54.
13. Schust J, Sperl B, Hollis A et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006; 13: 1235-42.
14. Hedvat M, Huszar D, Herrmann A et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-97.
15. Perkins ND. Integrating cell-signaling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
16. Basseres D, Baldwin A. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25: 6817-30.
17. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
18. Lin Y-W, Yang F-J, Chen C-L et al. Free radical scavenging activity and antiproliferative potential of Polygonum cuspidatum root extracts. J Nat Med 2010; 64: 146-52.
19. Srinivas G, Babykutty S, Sathiadevan PP et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev 2007; 27: 591-608.
20. Savouret J, Quesne M. Resveratrol and cancer: a review. Biomed Pharmacother 2002; 56: 84-7.
21. Liu J, Zhang Q, Chen K et al. Small-molecule STAT3 signaling pathway modulators from Polygonum cuspidatum. Planta Med 2012; 78: 1568-70.
22. Narazaki M, Witthuhn BA, Yoshida K et al. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Nat Acad Sci USA 1994; 91: 2285-9.
23. Duhé RJ, Evans GA, Erwin RA et al. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Nat Acad Sci USA 1998; 95: 126-31.
24. Ahmad R, Raina D, Meyer C et al. Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179. J Biol Chem 2006; 281: 35764-9.
25. Pandey MK, Sung B, Kunnumakkara AB et al. Berberine modifies cysteine 179 of IκBα kinase, suppresses nuclear factor-κB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 2008; 68: 5370-9.
26. Pandey MK, Sandur SK, Sung B, et al. A tetrahydroxychalcone, inhibits nuclear factor (NF)-κB and NF-κB-regulated gene expression through direct inhibition of IκBα kinase β on cysteine 179 residue. J Biol Chem 2007; 282: 17340-50.
27. Jayatilake GS, Jayasuriya H, Lee E-S et al. Kinase inhibitors from Polygonum cuspidatum. J Nat Prod 1993; 56: 1805-10.
28. Muto A, Hori M, Sasaki Y et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007; 6: 987-94.
29. Escarcega R, Fuentes-Alexandro S, Garcia-Carrasco M et al. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol 2007; 19: 154-61.
30. Chiou W, Liao J, Huang C et al. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signaling complexes. Br J Pharmacol 2010; 161: 321-35.
31. Singh SB, Graham PL, Reamer RA et al. Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues. Bioorg Med Chem Lett 2001; 11: 3143-6.
32. Li YB, Lin ZQ, Zhang ZJ et al. Protective, antioxidative and antiapoptotic effects of 2-methoxy-6-acetyl-7- methyljuglone. Planta Med 2011; 77: 354-61.